References
- 1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42.10.1212/WNL.17.5.427
- 2. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: record linkage studies. J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):215-21..10.1136/jnnp.2009.17546319726405
- 3. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson’s disease. Ann Neurol. 1985 May;17(5):505-9.10.1002/ana.4101705144004173
- 4. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH. Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. Int J Cancer. 2012 Oct 15;131(8):1904-11.10.1002/ijc.27443363676922278152
- 5. Skibba JL, Pinckley J, Gilbert EF, Johnson RO. Multiple primary melanoma following administration of levodopa. Arch Pathol. 1972 Jun;93(6):556-61.
- 6. Sandyk R. Accelerated growth of malignant melanoma by levodopa in Parkinson’s disease and role of the pineal gland. Int J Neurosci. 1992 Mar;63(1-2):137-40.10.3109/002074592089866631342025
- 7. Kincannon J, Boutzale C. The physiology of pigmented nevi. Pediatrics. 1999 Oct;104(4 Pt 2):1042-5.10.1542/peds.104.S5.1042
- 8. Gurney H, Coates A, Kefford R. The Use of L-Dopa and Carbidopa in Metastatic Malignant-Melanoma. Journal of Investigative Dermatology. 1991 Jan;96(1):85-7.10.1111/1523-1747.ep125158961987300
- 9. Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, et al. Nonfatal cancer preceding Parkinson’s disease: A case-control study. Epidemiology. 2002 Mar;13(2):157-64.10.1097/00001648-200203000-0001011880756
- 10. Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology. 2006 Sep;17(5):582-7.10.1097/01.ede.0000229445.90471.5e16837822
- 11. Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK, et al. Risk of cancer after the diagnosis of Parkinson’s disease: A historical cohort study. Movement Disord. 2005 Jun;20(6):719-25.10.1002/mds.2040115704188
- 12. Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Movement Disord. 2007 Jul 15;22(9):1252-7.10.1002/mds.2139717534943
- 13. Devine MJ, Plun-Favreau H, Wood NW. Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer. 2011 Nov;11(11):812-+.10.1038/nrc315022020207
- 14. Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease. J Neural Transm. 2011 Aug;118(8):1199-207.10.1007/s00702-011-0580-221298300
- 15. Pan TH, Li XQ, Jankovic J. The association between Parkinson’s disease and melanoma. International Journal of Cancer. 2011 May 1;128(10):2251-60.10.1002/ijc.2591221207412
- 16. Wick MM, Byers L, Frei E, 3rd. L-dopa: selective toxicity for melanoma cells in vitro. Science. 1977 Jul 29;197(4302):468-9.10.1126/science.877570877570
- 17. Gurney H, Coates A, Kefford R. The Use of L-Dopa and Carbidopa in Metastatic Malignant-Melanoma. Journal of Investigative Dermatology. 1991 Jan;96(1):85-7.10.1111/1523-1747.ep125158961987300
- 18. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat Disord. 2003 Aug;9(6):321-7.10.1016/S1353-8020(03)00040-312853231
- 19. Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease. Mov Disord. 2010 Sep 15;25(12):1801-8.10.1002/mds.2300620669311
- 20. Inzelberg R, Flash S, Friedman E, Azizi E. Cutaneous malignant melanoma and Parkinson disease: Common pathways? Ann Neurol. 2016 Dec;80(6):811-20.10.1002/ana.2480227761938
- 21. Rigel DS, Patel Z, Bolognia J, Eichler C, Ellis DL, Friedman RJ. Evaluation of Parkinson’s disease (PD) prevalence in patients with malignant melanoma (MM). Movement Disord. 2006;21:S58-S.
- 22. Baade D, Fritschi L, Freedman DM. Mortality due to amyotrophic lateral sclerosis and Parkinson’s disease among melanoma patients. Neuroepidemiology. 2007;28(1):16-20.10.1159/00009785117164565
- 23. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson’s disease. British Journal of Cancer. 2005 Jan 17;92(1):201-5.10.1038/sj.bjc.6602279236175315583688
- 24. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Cancer risk in association with Parkinson disease: A population-based study. Parkinsonism Relat D. 2010 Mar;16(3):186-90.10.1016/j.parkreldis.2009.11.00519945903
- 25. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiology Biomarkers & Prevention. 2007 Jun;16(6):1260-5.10.1158/1055-9965.EPI-07-003817548694
- 26. Sun LM, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH. Analysis of Parkinson’s Disease and Subsequent Cancer Risk in Taiwan: A Nationwide Population-Based Cohort Study. Neuroepidemiology. 2011;37(2):114-9.10.1159/00033148921986194
- 27. Lai SW, Liao KF, Lin CH, Tsai PY, Sung FC. Parkinson’s disease and lung cancer: A population-based case-control study in Taiwan. Geriatr Gerontol Int. 2013 Jan;13(1):238-40.10.1111/j.1447-0594.2012.00919.x23286570
- 28. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Neurology. 2007 Mar 20;68(12):A258-A.
- 29. Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in Parkinson’s disease. Front Neuroendocrin. 2009 Jul;30(2):142-57.10.1016/j.yfrne.2009.04.01419410597
- 30. Giovannelli P, Di Donato M, Giraldi T, Migliaccio A, Castoria G, Auricchio F. Targeting rapid action of sex-steroid receptors in breast and prostate cancers. Front Biosci-Landmrk. 2011 Jun 1;16:2224-32.10.2741/384921622172
- 31. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol. 2000 Jun;247(6):429-34.10.1007/s00415007017110929271
- 32. Qiu LX, Yuan H, Yu KD, Mao C, Chen B, Zhan P, et al. Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46,281 subjects. Breast Cancer Res Treat. 2010 Jun;121(3):703-8.10.1007/s10549-009-0636-219936916
- 33. Cai QL, Wang Z, Zhang W, Guo XM, Shang ZQ, Jiang N, et al. Association between glutathione S-transferases M1 and T1 gene polymorphisms and prostate cancer risk: a systematic review and meta-analysis. Tumor Biol. 2014 Jan;35(1):247-56.10.1007/s13277-013-1030-623888321
- 34. Wang TF, Wang B. Association between Glutathione S-transferase M1/Glutathione S-transferase T1 polymorphisms and Parkinson’s disease: A meta-analysis. Journal of the Neurological Sciences. 2014 Mar 15;338(1-2):65-70.10.1016/j.jns.2013.12.01824382428
- 35. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol. 2000 Jun;247(6):429-34.10.1007/s00415007017110929271
- 36. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson’s disease. British Journal of Cancer. 2005 Jan 17;92(1):201-5.10.1038/sj.bjc.6602279236175315583688
- 37. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH. Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. International Journal of Cancer. 2012 Oct 15;131(8):1904-11.10.1002/ijc.27443363676922278152
- 38. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared Predispositions of Parkinsonism and Cancer A Population-Based Pedigree-Linked Study. Arch Neurol-Chicago. 2012 Dec;69(12):1572-7.10.1001/archneurol.2012.226122945795
- 39. Kravitz E, Laitman Y, Hassin-Baer S, Inzelberg R, Friedman E. Parkinson’s disease genes do not segregate with breast cancer genes’ loci. Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1464-72.10.1158/1055-9965.EPI-13-047223765085
- 40. Routh JC, Crimmins CR, Leibovich BC, Elliott DS. Impact of Parkinson’s disease on continence after radical prostatectomy. Urology. 2006 Sep;68(3):575-7.10.1016/j.urology.2006.03.02516979722
- 41. Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol. 2015 Oct 7;21(37):10609-20.10.3748/wjg.v21.i37.10609458808326457021
- 42. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014 Oct;12(10):661-72.10.1038/nrmicro334425198138
- 43. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord. 2004 Jan;19(1):49-53.10.1002/mds.1064814743360
- 44. Ong EL, Goldacre R, Goldacre M. Differential risks of cancer types in people with Parkinson’s disease: a national record-linkage study. Eur J Cancer. 2014 Sep;50(14):2456-62.10.1016/j.ejca.2014.06.01825065294
- 45. Wirdefeldt K, Weibull CE, Chen H, Kamel F, Lundholm C, Fang F, et al. Parkinson’s disease and cancer: A register-based family study. Am J Epidemiol. 2014 Jan 1;179(1):85-94.10.1093/aje/kwt232386471424142916
- 46. Lin PY, Chang SN, Hsiao TH, Huang BT, Lin CH, Yang PC. Association Between Parkinson Disease and Risk of Cancer in Taiwan. Jama Oncol. 2015 Aug;1(5):633-40.10.1001/jamaoncol.2015.175226181771
- 47. Xie X, Luo XG, Xie ML. Association between Parkinson’s disease and risk of colorectal cancer. Parkinsonism Relat D. 2017 Feb;35:42-7.10.1016/j.parkreldis.2016.11.01127913126
- 48. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett. 2006 Mar 20;396(1):67-72.10.1016/j.neulet.2005.11.01216330147
- 49. Schernhammer E, Chen HL, Ritz B. Circulating melatonin levels: Possible link between Parkinson’s disease and cancer risk? Cancer Causes & Control. 2006 May;17(4):577-82.10.1007/s10552-005-9002-916596313
- 50. Sarkar C, Chakroborty D, Dasgupta PS, Basu S. Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. International Journal of Cancer. 2015 Aug 1;137(3):744-9.10.1002/ijc.29414443788425556636
- 51. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Jr., Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord. 2006 Apr;12(3):185-9.10.1016/j.parkreldis.2005.09.00416364673
- 52. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is Diabetes Mellitus an Independent Risk Factor for Colon Cancer and Rectal Cancer? Am J Gastroenterol. 2011 Nov;106(11):1911-21.10.1038/ajg.2011.301374145321912438
- 53. Powers KM, Smith-Weller T, Franklin GA, Longstreth WT, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat D. 2006;12(3):185-9.10.1016/j.parkreldis.2005.09.004
- 54. Ruiz-Martínez J, de la Riva P, Rodríguez-Oroz MC, Mondragón Rezola E, Bergareche A, Gorostidi A, et al. Prevalence of cancer in Parkinson’s disease related to R1441G and G2019S mutations in LRRK2. Mov Disord. 2014 May;29(6):750-5.10.1002/mds.2577824357540
- 55. Paisan-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology. 2010 Nov 2;75(18):1653-5.10.1212/WNL.0b013e3181fb446621041788
- 56. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5956-61.10.1073/pnas.093126210015630812719539
- 57. Waro BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson’s disease. Brain Behav. 2018 Jan;8(1).10.1002/brb3.858585362729568677
- 58. West AB, Dawson VL, Dawson TM. To die or grow: Parkinson’s disease and cancer. Trends Neurosci. 2005 Jul;28(7):348-52.10.1016/j.tins.2005.05.00215913799
- 59. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007 Oct 9;69(15):1542-50.10.1212/01.wnl.0000277638.63767.b817699801
- 60. Zanetti R, Loria D, Rosso S. Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res. 2006 Jun;16(3):201-6.10.1097/01.cmr.0000215043.61306.d716718266
- 61. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009 Oct 20;73(16):1286-91.10.1212/WNL.0b013e3181bd13a1276441719841380
- 62. Bajaj A, Driver JA, Schernhammer ES. Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010 May;21(5):697-707.10.1007/s10552-009-9497-620054708
- 63. Greenamyre JT, Hastings TG. Biomedicine. Parkinson’s--divergent causes, convergent mechanisms. Science. 2004 May 21;304(5674):1120-2.10.1126/science.109896615155938
- 64. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239-67.10.1146/annurev.pharmtox.44.101802.12185114744246
- 65. Kim RH, Mak TW. Tumours and tremors: how PTEN regulation underlies both. British Journal of Cancer. 2006 Mar 13;94(5):620-4.10.1038/sj.bjc.6602994236120416495927
- 66. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Navajas RFC. Smoking and Parkinson’s disease: Systematic review of prospective studies. Movement Disord. 2004 Jun;19(6):614-21.10.1002/mds.2002915197698